Trial Profile
Safety analysis, correlation with response and previous treatments of the association of everolimus (EVE) and exemestane (EXE) in 181 metastatic breast cancer patients (MBC)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 22 Jan 2016
Price :
$35
*
At a glance
- Drugs Everolimus (Primary) ; Exemestane (Primary)
- Indications Breast cancer
- Focus Adverse reactions
- 22 Jan 2016 New trial record